A pioneering pilot study at Be Well Hospital in Chennai, India, has unveiled the astounding potential of Nichi-BRITE Beta glucans in transforming Parkinson’s disease treatment. These exceptional food supplements, derived from the AFO-202 strain of Aureobasidium Pullulans, led to significant enhancements in patients’ Unified Parkinson’s Disease Rating Scale (UPDRS) and constipation scores after 90 days of administration.
Parkinson’s disease, a distressing neurological condition, impacts millions of individuals globally. Cutting-edge research is progressively uncovering the pivotal connection between gut health and neurological disorders like Parkinson’s. Nichi-BRITE Beta glucans have demonstrated the capacity to tame detrimental gut bacteria while fostering the growth of beneficial microbiota.
Dr. Dedeepiya, a co-author of the study, expressed excitement about Nichi-BRITE’s potential as an adjunct therapy for synucleinopathies such as Parkinson’s disease and multiple system atrophy. Dr. Nithyanandam, the study’s neurologist, underscored the importance of conducting more comprehensive studies to assess Nichi-BRITE’s full potential.
During a World Parkinson’s Day webinar, Prof. Muralidhar Hegde from Houston Methodist Research, USA, discussed the crucial role of alpha-synuclein abnormalities in the onset of neurodegenerative diseases. Dr. Rukmini Mridula from Hyderabad shed light on the rising prevalence of young-onset Parkinson’s disease cases in India.
The promising results from this pilot study suggest that Nichi-BRITE Beta glucans could soon become an essential weapon in the fight against Parkinson’s disease, offering a beacon of hope for millions of patients worldwide.
